Good question.
I think social scientists refer to this
Good question.
I think social scientists refer to this as a "crisis of confidence".
The marginal buyer aka those who could or would buy the stock are suffering a "crisis" of believing their potential purchase will result in an immediate loss.
As they refrain and wait for a "safer" purchase price, the next set of potential buyers behind them aka the new marginal buyers in the queue face the same decision and make the same decision as the previous group. This process repeats and repeats until a "new" clearing price is found. This new clearing price is the price at which a majority of all the previously queued potential buyers now believe there exists new buyers behind them who are willing to pay "more" than they are. All of the preceding assumes the item in question to be purchased possess an intrinsic value that is higher than the implied value of the asset given its current price.
The stock, like any stock, will continue to fall in price until new buyers show up who the current marginal buyer believes will pay a higher price than herself. Until this happens the stock, like any stock, will continue to fall in price.
The way our unique American style capitalism works is that managements of public companies are made responsible for communicating to the market place information and assurances to that information about the viability of their company's intrinsic value (whether its growing, stagnant or contracting).
To the extent that this communication does not happen or happens infrequently or poorly, current market prices will tend to reflect this attribute of a management's performance more than others.
If stock prices reflect the total sum of available 'news' about and on the company, then the job of disseminating that news and its timing and veracity is the primary job of management to the financial market place. The stock price can then be seen as the closest proxy to a management's veracity and skill at communicating information in a timely manner allowing all potential buyers of its stock to assess the company's current intrinsic value. As new information is learned either from management or from the market in which the company competes, this information will be incorporated into the stock price by the next marginal buyer.
Hope this helps answer your question.
Stay safe
TSOV
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...
Continue Reading
Top 5 Most Recently Viewed Articles
In-Silico Clinical Trials Market Overview The in-silico clinical trials market is witnessing substantial growth, projected to reach USD 6.39 billion in the near future. This transformation reflects a significant shift in how pharmaceutical and medical technology companies approach drug development and clinical evaluation. By leveraging advanced digital technologies,...
Continue Reading
Longeveron Inc. Leadership Evolution Longeveron Inc. has recently made pivotal updates to its leadership team, signaling significant strategic shifts within the company. Than Powell is stepping up as the Interim CEO, while Dr. Joshua Hare, a cornerstone of the company, takes on the role of Executive Chairman of the Board. These changes come as the company aims to enhance...
Continue Reading
Aebi Schmidt Group's Strategic Vision After Merger Aebi Schmidt Group is actively trading under the ticker symbol "AEBI" after completing an exciting merger with The Shyft Group. The organization is well-positioned with a robust balance sheet, focusing on executing its post-merger strategies effectively. Amidst a dynamic operating environment, the company's commitment to...
Continue Reading
Unibail-Rodamco-Westfield's Commitment to Sustainability Unibail-Rodamco-Westfield, often abbreviated as URW, has accomplished an impressive feat by receiving a top ‘A’ rating from CDP for the seventh consecutive year. This recognition is a testament to the company's continuous efforts and transparent actions in combating climate change, all structured under its...
Continue Reading
Big Moves in Private Equity: Genstar's New Addition What’s the deal here? Genstar Capital, that powerhouse in private equity, just scored big by bringing John Kufner on board as part of their Strategic Advisory Board. This isn’t just another hire; it's a strategic chess move. Kufner isn’t your run-of-the-mill executive—he's been around the block more than a few...
Continue Reading